Ursodeoxycholic acid and severe COVID-19 outcomes in a cohort study using the OpenSAFELY platform.

ABSTRACT:

Background

Biological evidence suggests ursodeoxycholic acid (UDCA)-a common treatment of cholestatic liver disease-may prevent severe COVID-19 outcomes. We aimed to compare the hazard of COVID-19 hospitalisation or death between UDCA users versus non-users in a population with primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC).

Methods

With the approval of NHS England, we conducted a population-based cohort study using primary care records between 1 March 2020 and 31 December 2022, linked to death registration data and hospital records through the OpenSAFELY-TPP platform. Cox proportional hazards regression was used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association between time-varying UDCA exposure and COVID-19 rela

SUBMITTER: Costello RE 

PROVIDER: S-EPMC11576861 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature